# Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Source: https://onco.cc/trials/nct05862012/  
OnCo record `nct05862012` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ISB 2001 in Multiple myeloma, run by Ichnos Sciences SA, now recruiting.

## Summary

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) is a phase 1 interventional study registered as NCT05862012 by Ichnos Sciences SA, with 200 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-07. Interventions recorded: ISB 2001, ISB 2001. Conditions recorded: Relapsed/Refractory Multiple Myeloma.

Linked to the drug ISB 2001 because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05862012
- Phase: 1
- Setting: A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
- Sponsor: Ichnos Sciences SA
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05862012: https://clinicaltrials.gov/study/NCT05862012

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [ISB 2001](https://onco.cc/drugs/isb-2001/)

---
JSON: https://onco.cc/api/v1/entities/nct05862012.json